Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corporation amended its Definitive Proxy Statement to correct the number of shares outstanding: 13,413,917 shares were outstanding and entitled to vote as of March 23, 2026. The amendment is clerical only and makes no other changes to the proxy materials for the Annual Meeting on May 18, 2026.
The Proxy Statement describes the Annual Meeting agenda (elect nine directors; ratify auditors; advisory vote on executive compensation), voting procedures, director nominees and detailed governance and executive compensation policies, including 2025 pay outcomes and equity incentive structures.
Chemed Corporation is asking stockholders to vote at its May 18, 2026 annual meeting on three main items: electing nine directors, ratifying the independent auditor, and approving executive compensation in an advisory vote. Stockholders of record on March 23, 2026, when 14,614,676 shares were outstanding, may vote in person or by mail, phone, or Internet.
The Board uses a majority voting standard in uncontested director elections and all incumbent nominees have pre-submitted resignations if they fail to receive majority support. Non-employee directors receive $80,000 in annual cash retainers plus meeting fees and about $160,394 in fully vested stock awards, with additional retainers for committee roles and the Chair.
For 2025, CEO Kevin J. McNamara’s total compensation was $12.9 million, with roughly 72.9% performance-based. The pay program ties annual bonuses mainly to Adjusted EPS and return on assets, and long-term incentives to three-year cumulative Adjusted EPS and relative Total Shareholder Return versus a defined peer group. In the 2025 say-on-pay vote, 88.63% of shares voting supported Chemed’s executive compensation program.
Chemed Corporation president and CEO Kevin J. McNamara completed an open-market sale of company Capital Stock. On March 27, 2026, he sold 1,500 shares at a weighted average price of $369.37 per share in multiple trades.
The shares were sold at prices ranging from $365.76 to $373.24. Following this transaction, McNamara directly holds 92,219 shares of Chemed stock.
Chemed Corporation filed a Form 144 notifying a proposed sale of 1,500 shares of Common stock. The notice lists Merrill Lynch as the broker and an effective filing date of 03/27/2026. The filing also records two reported sales by Kevin McNamara of 1,000 shares each on 03/12/2026.
Chemed Corp (CHE) Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Chemed common stock, representing 0% of the class as disclosed in the filing dated 03/13/2026. The filing explains an internal realignment at Vanguard on 01/12/2026 that caused disaggregated reporting by subsidiaries; no beneficial ownership is claimed here.
CHEMED CORP president and CEO Kevin J. McNamara sold 2,000 shares of Capital Stock in an open-market transaction at a weighted average price of $403.18 per share. Following this sale, he directly holds 93,719 shares. The trade was executed through multiple transactions at prices between $399.31 and $404.68.
Chemed Corporation reports a Form 144 notice reflecting proposed sales of Common Stock by Kevin McNamara related to stock awards and exercises. The filing lists award/exercise events dated 02/17/2023, 05/01/2023, and 05/02/2023, including awards of 492 and 498 shares.
Chemed Corporation operates two main businesses: VITAS hospice and palliative care and Roto-Rooter plumbing and restoration services, all managed in a decentralized structure. VITAS generates over 95% of its revenue from Medicare and Medicaid per-diem payments, making government reimbursement policies critical to its results.
The filing highlights extensive regulatory oversight, including hospice Conditions of Participation, anti-kickback and false-claims rules, licensing and Certificate of Need laws, and evolving privacy and cybersecurity requirements. VITAS previously operated under a five-year corporate integrity agreement that concluded in 2023, and in 2025 experienced a cyberattack in which a threat actor accessed protected health information.
Roto-Rooter faces fragmented but intense competition and is sensitive to weather-driven demand and labor availability for licensed plumbers. As of December 31, 2025, Chemed employed 15,811 people and emphasized safety, training and retention programs. Recent growth initiatives included multiple small Roto-Rooter franchise purchases and VITAS’s $85.0 million cash acquisition of Covenant hospice operations and an assisted living facility.
Chemed Corporation reported mixed fourth-quarter 2025 results and issued 2026 guidance. Q4 service revenues and sales were $639.3 million, essentially flat year over year, while net income declined to $76.8 million from $90.3 million. Diluted EPS fell to $5.48 from $6.02.
VITAS net revenue grew 1.9% to $418.8 million, supported by higher days-of-care and Medicare reimbursement, though gross margin excluding Medicare Cap fell to 27.3%. Roto-Rooter revenue declined 3.7% to $220.6 million, and adjusted EBITDA dropped 21.1% with margin down to 21.5%.
For full-year 2025, Chemed generated service revenues and sales of $2.53 billion and net income of $265.2 million, or $18.34 diluted EPS. Adjusted diluted EPS was $21.55. The company ended 2025 with $74.5 million in cash, no debt, and repurchased 400,000 shares for $174.6 million.
Management expects 2026 VITAS revenue to grow 5.5%–6.5% before Medicare Cap and Roto-Rooter revenue to grow 3.0%–3.5%. Adjusted diluted EPS is projected between $23.25 and $24.25, above 2025’s $21.55, with about 55% of adjusted earnings and EBITDA weighted to the year’s second half.